Adaptive: Why Analysts See It as a Dominant Force
Guggenheim rated ADPT a "Buy." It dominates blood cancer testing and will see major growth. "Shares are currently undervalued."
NOTRELOAD AI
Oklo Stock Downgrade: Why BofA Changed Its Tune
BofA downgraded Oklo stock. They like nuclear long-term, but feel the current high price is too risky now due to unrealistic valuation.
Evercore ISI Initiates Street-High Price Target for CoreWeave
CoreWeave received an Outperform rating and a $175 price target from Evercore ISI.
Energy Drink Stocks Get a Boost: Why Celsius and Alani Are Looking Up
Celsius stock got a big upgrade ($70 target). The brand is growing again, and Alani is expected to boost sales via the new Pepsi deal.
Array: Analysts Predict a Bright Future
Solar tracker giant Array got Buy ratings and $11 price targets. Focus on utility-scale and turnaround boosted confidence.
Major Buy Signal! Jefferies Initiates Coverage on Nuvation Bio
Jefferies issued a Buy rating on Nuvation Bio with a $10 price target, citing its FDA-approved lead drug, strong pipeline potential, and cash reserves extending into 2028.